Kolexia
Bedossa Pierre Anatomie et cytologie
Bedossa Pierre
Anatomie et cytologie
Hôpital Beaujon
Clichy, France
319 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Stéatose hépatique non alcoolique Fibrose Stéatose hépatique Cirrhose du foie Maladies du foie Stéatose hépatique alcoolique Hépatite Tumeurs du foie Carcinome hépatocellulaire

Collaborateurs

Voir plus
Paradis Valerie
Paradis Valerie
Hôpital Beaujon, Clichy, France
Couvelard Anne
Couvelard Anne
Hôpital Bichat-Claude-Bernard, Paris, France
Clement Karine
Clement Karine
Hôpital Pitie Salpetriere, Paris, France
Valla Dominique
Valla Dominique
Hôpital Beaujon, Clichy, France

Industries

Voir plus
Intercept Pharmaceuticals
6 collaboration(s)
Dernière en 2023
MSD
3 collaboration(s)
Dernière en 2021
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
The New England journal of medicine   16 février 2024
MAESTRO-NASH: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
Essai Clinique (Madrigal Pharmaceuticals, Inc.)   15 février 2024
ENLIVEN: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
Essai Clinique (89bio, Inc.)   09 février 2024
Prospective comparison of ATI and CAP for liver steatosis diagnosis in patients with NAFLD and type 2 diabetes.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association   08 décembre 2023
Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH.
Journal of hepatology   15 novembre 2023
REGENERATE: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Essai Clinique (Intercept Pharmaceuticals)   13 octobre 2023
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
The lancet. Gastroenterology & hepatology   03 octobre 2023
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.
Alimentary pharmacology & therapeutics   02 octobre 2023
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
Alimentary pharmacology & therapeutics   29 août 2023
Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests.
Nature communications   26 août 2023